Skip to content
Business websites
Business websites
J&J Innovative Medicine
J&J MedTech
J&J Innovative Medicine
Business websites
JNJ.com
NewPharm.com
JnJMedTech.com
J&J MedTech
US • English
Choose your country or region
China
中国人
France
Français
India
English
Japan
日本
Switzerland
Deutsch
Switzerland
English
Switzerland
Français
US
English
United Kingdom
English
Latest News
Back
Innovation
Caring & giving
Personal stories
Health & wellness
Our heritage
Our Company
Back
Discover J&J
Back
Our Credo
Our Leadership
Code of Business Conduct
Corporate Reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Digital Solutions
J&J Health & Wellness Solutions
Office of the Chief Medical Officer
Veterans, Military & Military Families
Innovative Medicine
MedTech
Our societal impact
Back
Global Health Equity
Global environmental sustainability
Suppliers
Back
Responsible Supply Base
Supplier Enabled Innovation
Supplier Resources
Careers
Back
Life at J&J
Diversity, Equity and Inclusion
Career Areas of Impact
Students
Re-Ignite Program
Contract & Freelance Partner Opportunities
Career Stories
Investors
Back
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Latest News
Back
Innovation
Caring & giving
Personal stories
Health & wellness
Our heritage
Our Company
Back
Discover J&J
Back
Our Credo
Our Leadership
Code of Business Conduct
Corporate Reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Digital Solutions
J&J Health & Wellness Solutions
Office of the Chief Medical Officer
Veterans, Military & Military Families
Innovative Medicine
MedTech
Our societal impact
Back
Global Health Equity
Global environmental sustainability
Suppliers
Back
Responsible Supply Base
Supplier Enabled Innovation
Supplier Resources
Careers
Back
Life at J&J
Diversity, Equity and Inclusion
Career Areas of Impact
Students
Re-Ignite Program
Contract & Freelance Partner Opportunities
Career Stories
Investors
Back
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Search Query
Submit Search
Dictate search request
Recently Viewed
Listening...
Show Search
Menu
Home
/
Media Center
/
Press releases
Press releases
Press Releases
Search Query
Submit Search
Dictate search request
Listening...
1,935 Results
Date
All Dates (1935)
Past 30 days (15)
2023 (140)
2022 (125)
2021 (185)
2020 (110)
2019 (130)
2018 (166)
2017 (196)
2016 (125)
Topic
All (1935)
Corporate (131)
ESG (1)
Financial (282)
Global Health Equity (59)
Leadership (20)
Medical technologies (257)
Pharmaceuticals (859)
Research (42)
1,935 results
Filters
Date
All Dates (1935)
Past 30 days (15)
2023 (140)
2022 (125)
2021 (185)
2020 (110)
2019 (130)
2018 (166)
2017 (196)
2016 (125)
Topic
All (1935)
Corporate (131)
ESG (1)
Financial (282)
Global Health Equity (59)
Leadership (20)
Medical technologies (257)
Pharmaceuticals (859)
Research (42)
Sort By:
Newest
Newest
Relevance
Oldest
May 6, 2024
TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non–muscle-invasive bladder cancer, respectively
Updated results reinforce the potential of TAR-210 to transform treatment of non–muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterations
Read more
May 3, 2024
Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery
Study highlights opportunity for treatment intensification in this population since approximately 50% of patients with high-risk localized prostate cancer (HRLPC) experience disease recurrence within two years of surgery
Read more
May 3, 2024
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non–muscle-invasive bladder cancer
New data from Phase 2b SunRISe-1 study show rapid achievement of complete response (CR) with 98% achieving a CR within 12 weeks TAR-200 provides durable CRs in patients with Bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC) with carcinoma in situ – a disease area with limited treatment options for patients
Read more
May 3, 2024
Johnson & Johnson Highlights Commitment to Transform Treatment of Retinal Diseases at ARVO 2024
Company to present, across eight data presentations, new real-world research on the economic value of genetic testing for retinal diseases and the role of automatic deep-learning based algorithms for geographic atrophy Johnson & Johnson to debut first-of-its-kind EYE-RD Global Registry, aiming to bridge knowledge gaps for inherited retinal diseases
Read more
May 1, 2024
Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment of patients with ulcerative colitis and Crohn’s disease
Submission included data from the Phase 3 QUASAR program in ulcerative colitis and the Phase 3 GALAXI program in Crohn’s disease, which each achieved their primary endpoints1,2
Read more
May 1, 2024
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization
The Plan would resolve 99.75% of all pending talc lawsuits against Johnson & Johnson and its affiliates in the United States
Read more
April 29, 2024
Johnson & Johnson Receives Positive CHMP Opinion Recommending Full Approval for SIRTURO® (bedaquiline) for Treatment of Multidrug-Resistant Tuberculosis
CHMP recommends Conditional Marketing Authorisation be converted into standard Marketing Authorisation Recommendation supported by results from the Phase 3 STREAM Stage 2 study, which show bedaquiline-containing regimens offer significant improvement compared to other available therapies
Read more
April 26, 2024
Johnson & Johnson receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
This positive CHMP opinion establishes amivantamab as a new option, and the first fully-human EGFR-MET bispecific antibody, in the first-line treatment of EGFR exon 20 insertion-mutated NSCLC The recommendation is supported by data from the Phase 3 PAPILLON study, which showed amivantamab plus chemotherapy significantly improved progression-free survival in adult patients, versus chemotherapy alone1
Read more
April 22, 2024
Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)
Read more
April 22, 2024
CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy
Expanded indication for this one-time infusion may provide patients with a potential period away from their multiple myeloma treatment as early as first relapse1 Approval is based on results from the PHASE 3 CARTITUDE-4 study, in which treatment with cilta-cel in 1-3 prior lines of therapy reduced the risk of disease progression or death by 74 percent compared to standard therapies1
Read more
Load More
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue